On February 25, 2021 Kuano reported that the o2h human health EIS Fund is leading a consortium of investors participating in a pre-seed round in order to establish proof of concept of our unique quantum modelling and AI-inspired drug discovery technology (Press release, Kuano, FEB 25, 2021, View Source [SID1234639047]). Our platform, which focuses on modelling the quantum transition state of the catalytic site of enzymes, brings a new perspective to designing better enzyme inhibitors. This approach overcomes key limitations of existing discovery technologies and enables us to develop drugs with improved potency and selectivity while minimizing susceptibility to resistance caused by mutations.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Kuano is establishing an early stage pipeline of inhibitors of attractive drug targets in areas such as protein degradation and immunometabolism. Simultaneously we are seeking collaborative deals with pharma and biotech to leverage our technology platform to develop novel inhibitors to challenging high value enzymes.
o2h Ventures has a track record of nurturing and investing in some of the most innovative early stage biotech companies in the UK. Joining o2h Ventures in this investment round is Meltwind, Syndicate Room and Cambridge Angels.
Dr. Vid Stojevic, Co-Founder CEO of Kuano, said:
o2h Ventures have been supportive over the last six months to develop our business model and also to identify high value drug targets. I am very excited to work with a fund with the deep expertise and network that o2h Ventures can bring in the biotech space.
Sunil Shah, CEO at o2h Ventures said:
We are very pleased to back Kuano in this venture. Being able to more accurately understand and predict subtle changes around enzyme’s active sites could unlock faster opportunities to push inhibitors for difficult drug targets through discovery and development. Vid and Dave using their knowledge of quantum physics and Parminder and Jarryl with their previous big pharma and biotech drug discovery experience make a great team to both develop the platform and advance the drug assets from this. I am very much looking forward to joining the board and supporting this venture.